8-K: Masimo Reports Strong Third Quarter, Raises Full-Year EPS Guidance

Masimo Corporation announced positive third-quarter results driven by its healthcare segment, and increased its full-year non-GAAP operating margin and EPS guidance.

Summary

• Masimo's consolidated revenue for the third quarter of 2024 was $504.6 million, with healthcare revenue at $343.3 million and non-healthcare revenue at $161.3 million.
• Healthcare revenue increased by 11.5% on a reported basis and 11.7% on a constant currency basis.
• The company shipped 60,500 noninvasive technology boards and instruments during the quarter.
• GAAP operating income was $30.1 million, while non-GAAP operating income reached $80.8 million.
• GAAP net income was $9.8 million, or $0.18 per diluted share, and non-GAAP net income was $52.9 million, or $0.98 per diluted share.
• Masimo has updated its full-year 2024 non-GAAP revenue guidance to $2,075 to $2,105 million, with healthcare revenue expected to be $1,390 to $1,400 million and non-healthcare revenue between $685 and $705 million.
• The company increased its full-year non-GAAP operating income guidance to $325 to $336 million and non-GAAP earnings per diluted share guidance to $3.95 to $4.10.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong healthcare revenue growth, improved margins, and increased full-year EPS guidance. The company's strategic focus and management's confidence contribute to the positive outlook. However, the decline in non-healthcare revenue and some risks temper the overall sentiment slightly.

Positives

• Masimo reported strong third-quarter performance, driven by its core healthcare segment.
• The company experienced a seamless transition since its Annual Meeting with no disruption to business or departures of critical talent.
• Masimo is focusing on sizable market opportunities and reducing spending in areas not contributing to long-term growth.
• The company is progressing on its strategic review of the consumer business.
• Masimo increased its full-year non-GAAP operating margin and EPS guidance.
• Healthcare gross margin improved by 260 basis points in Q3 2024.
• Non-Healthcare gross margin improved by 200 basis points in Q3 2024.
• Non-GAAP EPS grew by 31% in Q3 2024.

Negatives

• Non-healthcare revenue declined by 6% on a reported and constant currency basis in Q3 2024.
• Consolidated revenue growth was 0% year-to-date on a reported and constant currency basis.
• Non-Healthcare revenue declined by 17% year-to-date on a reported basis and 16% on a constant currency basis.
• Non-Healthcare gross margin declined by 110 basis points year-to-date.
• GAAP earnings per share decreased by 10% in Q3 2024.

Risks

• The company is dependent on Masimo SET and Masimo rainbow SET products and technologies for substantially all of its revenue.
• There is a risk of failure in protecting intellectual property and exposure to competitors' intellectual property claims.
• The markets in which Masimo sells its products and technologies are highly competitive.
• There is a risk of failure to continue developing innovative products and technologies.
• The company faces risks related to integrating Sound United's brands into its business.
• There is a risk of not obtaining expected returns from intangible assets.
• The company is involved in ongoing litigation and related matters.
• There is uncertainty regarding the potential separation of the consumer business.
• Changes in general economic and/or industry-specific conditions could impact the company.
• Actions by third parties, including government agencies, could pose risks.

Future Outlook

Masimo has increased its full-year 2024 non-GAAP operating margin and EPS guidance, reflecting confidence in its position as it approaches the end of the year. The company is focused on long-term growth potential by capitalizing on opportunities, reviewing its product portfolio, and allocating resources to key projects.

Management Comments

• Michelle Brennan, Interim Chief Executive Officer of Masimo, stated that they are pleased with the strong third-quarter performance, driven by the healthcare segment.
• She also noted the seamless transition since the Annual Meeting and the focus on positioning Masimo for long-term growth.
• Management is allocating resources to fewer projects, concentrating on sizable market opportunities, and reducing spending in areas not contributing to long-term growth.
• The company is progressing on its strategic review of the consumer business and is focused on delivering the best outcome for shareholders.
• Management is confident in their position as they approach the end of 2024, as demonstrated by the increased full-year non-GAAP operating margin and EPS guidance.

Industry Context

Masimo's focus on its core healthcare segment aligns with the broader trend of medical technology companies prioritizing their most profitable and stable businesses. The strategic review of the consumer business suggests a potential shift in focus towards higher-margin areas. The company's emphasis on innovation and market opportunities is consistent with the competitive landscape of the medical device industry.

Comparison to Industry Standards

• Masimo's healthcare revenue growth of 11.7% constant currency is strong compared to some of its competitors in the medical device space, such as Medtronic and Philips, which have seen more modest growth in recent quarters.
• The improvement in non-GAAP gross margin to 53.9% is a positive sign, indicating better cost management and pricing power, which is a key metric for medical device companies.
• The increase in full-year non-GAAP EPS guidance suggests that Masimo is outperforming its initial expectations, which is a positive signal for investors compared to companies that have lowered guidance.
• Compared to companies like Edwards Lifesciences, which focus on specific high-growth areas, Masimo's strategic review of its consumer business suggests a similar move towards focusing on core strengths.
• The company's focus on R&D and innovation is in line with industry leaders like Stryker, which invest heavily in new product development to maintain a competitive edge.

Legal Proceedings

• The company is involved in various legal proceedings against Apple, and has updated its non-GAAP financial measures to exclude all expenses related to this litigation.

Stakeholder Impact

• Shareholders will benefit from the increased full-year EPS guidance and the company's focus on long-term growth.
• Employees are recognized for their commitment and energy during the seamless transition since the Annual Meeting.
• Customers will continue to receive innovative monitoring technologies and solutions.
• Suppliers will continue to be part of Masimo's supply chain.
• Creditors will be impacted by the company's financial performance and outlook.

Next Steps

• The company will continue its strategic review of the consumer business.
• Masimo will focus on allocating resources to key projects and market opportunities.
• The company will continue to execute on its strategy while enhancing shareholder value.
• Masimo will conduct its third quarter 2024 investor conference call on November 5, 2024.

Key Dates

Keywords

Masimo, Healthcare, Non-Healthcare, Financial Results, Earnings, Revenue, Operating Income, Net Income, EPS, Guidance, Pulse Oximetry, Medical Devices